The remaining 2% of CML cases express atypical BCR::ABL1 fusions involving different BCR and/or ABL1 exons; recognition of these cases is important for their clinical management [4]. Here, ABL1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.